Metabolon Selected for Membership in National Cancer Institute Research Group.RESEARCH TRIANGLE PARK Research Triangle Park, research, business, medical, and educational complex situated in central North Carolina. It has an area of 6,900 acres (2,795 hectares) and is 8 × 2 mi (13 × 3 km) in size. Named for the triangle formed by Duke Univ. , N.C. -- Metabolon, Inc., a leader in the discovery of biomarkers using metabolomics, today announced it has been selected as a member of the National Cancer Institute's (NCI See Liberate. ) Early Detection Research Network (EDRN EDRN Early Detection Research Network ). Metabolon's second project with NCI but first project as a member of the EDRN will be a collaboration with the University of Michigan (body, education) University of Michigan - A large cosmopolitan university in the Midwest USA. Over 50000 students are enrolled at the University of Michigan's three campuses. The students come from 50 states and over 100 foreign countries. to discover novel disease biomarkers for prostate cancer. The collaboration is funded by a grant from NCI as part of the EDRN Chair's Challenge program. "Membership in the EDRN is a great privilege," said Dr. John Ryals, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Metabolon. "Metabolon will be able to collaborate with other members to discover and develop biomarkers for the early diagnosis of cancers." The EDRN, established by NCI in early 2000, is a broad, interdisciplinary consortium whose work is aimed at both identifying and validating cancer biomarkers for use in early cancer detection. Metabolon will share its technology and metabolomics expertise with Dr. Arul Chinnaiyan of the University of Michigan on the prostate cancer project. "Metabolon is at the forefront in the emerging area of metabolomics, and we are extremely excited about embarking on this collaboration," said Dr. Chinnaiyan. "If metabolomic biomarkers can be identified for prostate cancer, Metabolon's technology platform may have applications in other cancers as well." About Metabolon Metabolon is an industry leader in the discovery of biomarkers through the use of metabolomics, a powerful scientific approach for the discovery and development of drugs and the early diagnosis of disease states. Metabolon's patent-pending technology is poised to dramatically impact drug discovery and development processes by accurately measuring the spectrum of biochemical changes and mapping these changes to metabolic pathways. Metabolon's technology can identify safer compounds for development, shorten the time for drugs to get to market and identify novel biomarkers for earlier disease detection. In conjunction with the NIH "Not invented here." See digispeak. NIH - The United States National Institutes of Health. , Metabolon was honored as a recipient of the 2005 March of Dimes
|
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion